{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:10:09Z","timestamp":1648566609262},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00391-020-01701-w","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:02:46Z","timestamp":1583312566000},"page":"263-272","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiples Myelom bei \u00c4lteren"],"prefix":"10.1007","volume":"53","author":[{"given":"Valentin","family":"Goede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"1701_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow\u00a0SH et\u00a0al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"1701_CR2","unstructured":"https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebsgeschehen\/Krebsgeschehen_download.pdf?__blob=publicationFile. Zugegriffen: 15. August 2019."},{"key":"1701_CR3","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cam4.1128","volume":"6","author":"H Gregersen","year":"2017","unstructured":"Gregersen\u00a0H et al (2017) The impact of comorbidity on mortality in multiple myeloma: a\u00a0Danish nationwide population-based study. Cancer Med 6:1807\u20131816","journal-title":"Cancer Med"},{"key":"1701_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00108-018-0529-8","volume":"60","author":"L Rasche","year":"2019","unstructured":"Rasche\u00a0L et\u00a0al (2019) Pathogenesis of multiple myeloma. Internist 60:3\u20139","journal-title":"Internist"},{"key":"1701_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar\u00a0SV et\u00a0al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"1701_CR6","unstructured":"Onkologie. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiples-myelom\/@@guideline\/html\/index.html. Zugegriffen: 15. August 2019."},{"key":"1701_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo\u00a0A et\u00a0al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J\u00a0Clin Oncol 33:2863\u20132869","journal-title":"J Clin Oncol"},{"key":"1701_CR8","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo\u00a0A et\u00a0al (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068\u20132074","journal-title":"Blood"},{"key":"1701_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt\u00a0M et\u00a0al (2017) A concise revised Myeloma Comorbidity Index as a\u00a0valid prognostic instrument in a\u00a0large cohort of 801 multiple myeloma patients. Haematologica 102:910\u2013921","journal-title":"Haematologica"},{"key":"1701_CR10","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","volume":"103","author":"J Caers","year":"2018","unstructured":"Caers\u00a0J et\u00a0al (2018) European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 103:1772\u20131784","journal-title":"Haematologica"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael\u00a0J et\u00a0al (2019) Treatment of multiple myeloma: aSCO and CCO joint clinical practice guideline. J\u00a0Clin Oncol 37:1228\u20131263","journal-title":"J Clin Oncol"},{"key":"1701_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman\u00a0S et\u00a0al (2017) Elderly patients with multiple myeloma: towards a\u00a0frailty approach? Curr Opin Oncol 29:315\u2013321","journal-title":"Curr Opin Oncol"},{"key":"1701_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdu210","volume":"26","author":"L Decoster","year":"2015","unstructured":"Decoster\u00a0L et\u00a0al (2015) Screening tools for multidimensional health problems warranting a\u00a0geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol 26:288\u2013300","journal-title":"Ann Oncol"},{"key":"1701_CR14","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile\u00a0SG et\u00a0al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J\u00a0Clin Oncol 36:2326\u20132347","journal-title":"J Clin Oncol"},{"key":"1701_CR15","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers\u00a0H et\u00a0al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J\u00a0Clin Oncol 32:2595\u20132603","journal-title":"J Clin Oncol"},{"key":"1701_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","volume":"38","author":"ME Hamaker","year":"2014","unstructured":"Hamaker\u00a0ME et\u00a0al (2014) The relevance of a\u00a0geriatric assessment for elderly patients with a\u00a0haematological malignancy\u2014a systematic review. Leuk Res 38:275\u2013283","journal-title":"Leuk Res"},{"key":"1701_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","volume":"9","author":"ME Hamaker","year":"2018","unstructured":"Hamaker\u00a0ME et\u00a0al (2018) The effect of a\u00a0geriatric evaluation on treatment decisions and outcome for older cancer patients\u2014a systematic review. J\u00a0Geriatr Oncol 9:430\u2013440","journal-title":"J Geriatr Oncol"},{"key":"1701_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jgo.2016.02.007","volume":"7","author":"A Magnuson","year":"2016","unstructured":"Magnuson\u00a0A et\u00a0al (2016) Geriatric assessment with management in cancer care: current evidence and potential mechanisms for future research. J\u00a0Geriatr Oncol 7:242\u2013248","journal-title":"J Geriatr Oncol"},{"key":"1701_CR19","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1002\/ajh.25310","volume":"94","author":"NY Saini","year":"2019","unstructured":"Saini\u00a0NY et al (2019) Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94:E2\u2013E5","journal-title":"Am J Hematol"},{"key":"1701_CR20","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin\u00a0C et\u00a0al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J\u00a0Clin Oncol 27:3664\u20133670","journal-title":"J Clin Oncol"},{"key":"1701_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel\u00a0JF et\u00a0al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N\u00a0Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"1701_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon\u00a0T et al (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301\u2013310","journal-title":"Blood"},{"key":"1701_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos\u00a0MV et\u00a0al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N\u00a0Engl J Med 378:518\u2013528","journal-title":"N Engl J Med"},{"key":"1701_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie\u00a0BG et al (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a\u00a0randomised, open-label, phase 3 trial. Lancet 389:519\u2013527","journal-title":"Lancet"},{"key":"1701_CR25","doi-asserted-by":"publisher","first-page":"60656","DOI":"10.18632\/oncotarget.19269","volume":"8","author":"A Larocca","year":"2017","unstructured":"Larocca\u00a0A et\u00a0al (2017) Emerging drugs and combinations to treat multiple myeloma. Oncotarget 8:60656\u201360672","journal-title":"Oncotarget"},{"key":"1701_CR26","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","volume":"129","author":"M Delforge","year":"2017","unstructured":"Delforge\u00a0M et\u00a0al (2017) How I manage the toxicities of myeloma drugs. Blood 129:2359\u20132367","journal-title":"Blood"},{"key":"1701_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00761-019-0573-6","volume":"25","author":"V Goede","year":"2019","unstructured":"Goede\u00a0V et\u00a0al (2019) Vom geriatrischen Assessment zur geriatrischen Intervention. Onkologe 25:776\u2013783","journal-title":"Onkologe"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-020-01701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00391-020-01701-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-020-01701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:24:24Z","timestamp":1614817464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00391-020-01701-w"}},"subtitle":["Praxiswissen f\u00fcr Geriater und Allgemeinmediziner"],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s00391-020-01701-w","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"value":"0948-6704","type":"print"},{"value":"1435-1269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>V.\u00a0Goede<\/b>: Finanzielle Interessen: Roche\u00a0\u2013 Advisory Board, Vortragshonorare, Reiseunterst\u00fctzung (Kongressbesuche)\u00a0| Janssen\u00a0\u2013 Advisory Board, Vortragshonorare, Reiseunterst\u00fctzung (Kongressbesuche)\u00a0| Gilead\u00a0\u2013 Advisory Board, Vortragshonorare\u00a0| AbbVie\u00a0\u2013 Advisory Board, Vortragshonorare\u00a0| Heel\u00a0\u2013 Vortragshonorare. Nichtfinanzielle Interessen: angestellter Oberarzt und Sektionsleiter, Sektion f\u00fcr Onkologische Geriatrie, Klinik f\u00fcr Geriatrie, St. Marien-Hospital, K\u00f6ln\u00a0| Mitgliedschaften: DGG, BDI, DGHO, EHA, SIOG\u00a0| Vice Chair der EHA Scientific Working Group Aging Hematology\u00a0| Board-Member des SIOG Science Education Committee\u00a0| Sprecher des DGHO-Programmkomitees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}